Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07050186

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

A Single Arm Open-Label Pilot Study to Investigate the Safety and Clinical Activity of Cemiplimab, A Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Incurable NUT Carcinoma (NC)

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic NUT Carcinoma Unresectable NUT Carcinoma

Interventions Biopsy Procedure Biospecimen Collection Cemiplimab Computed Tomography Digital Photography Magnetic Resonance Imaging Questionnaire Administration

Updated 2 times since 2025 Last updated: Sep 23, 2025 Started: Aug 15, 2025 Primary completion: Nov 20, 2030 Completion: Nov 20, 2035

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic NUT Carcinoma and Unresectable NUT Carcinoma and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States